Last reviewed · How we verify
Perindopril + Indapamide
Perindopril inhibits ACE to reduce angiotensin II formation and lower blood pressure, while indapamide acts as a thiazide-like diuretic to promote sodium and water excretion.
Perindopril inhibits ACE to reduce angiotensin II formation and lower blood pressure, while indapamide acts as a thiazide-like diuretic to promote sodium and water excretion. Used for Hypertension, Hypertension with left ventricular hypertrophy.
At a glance
| Generic name | Perindopril + Indapamide |
|---|---|
| Sponsor | Centre for Chronic Disease Control, India |
| Drug class | ACE inhibitor + thiazide-like diuretic combination |
| Target | Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Perindopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Indapamide is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing blood volume. Together, they provide complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Hypertension with left ventricular hypertrophy
Common side effects
- Cough
- Dizziness
- Hyperuricemia
- Hypokalemia
- Headache
- Fatigue
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs (PHASE4)
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes (PHASE3)
- Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India (PHASE4)
- Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perindopril + Indapamide CI brief — competitive landscape report
- Perindopril + Indapamide updates RSS · CI watch RSS
- Centre for Chronic Disease Control, India portfolio CI